Acute Respiratory Distress Syndrome (ARDS): Personalized Therapies and Beyond

Dear Colleagues,

ARDS was first recognized in 1967, and since then, significant strides have been made in the effort to find effective therapies. Nevertheless, despite more than 50 years of research, identifying new effective treatments for the acute respiratory distress syndrome (ARDS) is challenging. Personalized therapy to biological and clinical sub-phenotypes seems promising. Personalized interventions offer the chance to reduce heterogeneity, thus reproposing or newly testing treatments in another perspective. Moreover, ARDS is very heterogeneous syndrome, and understanding the interaction between lungs and other organs could improve our knowledge. The aim of this Special Issue is to publish papers on emerging opportunities for personalizing therapy for ARDS, from the identification of treatable traits to the recognition of target mechanisms, lungs–organs interaction, supportive therapies, new etiologies, and innovative clinical trial designs. Topics of interest include biological phenotypes, omics, physiological phenotypes, clinical phenotypes, ARDS definition, ARDS complications, lung–organs interactions in ARDS, etiology, and microbiota. We look forward to review articles, physiological papers, original research, preclinical experimental studies, meta-analyses, and systematic reviews.

With sadness, we regret to inform you about the passing of Prof. Dr. Paolo Pelosi, Topic Editor of this Topic, in May 2023. We are grateful for his many contributions to the Topic and the legacy his research has left.

Dr. Denise Battaglini
Topic Editor